A Single Arm Study Comparing ACC Supplement to CCS in Management of Hypoparathyroidism
NCT ID: NCT06288490
Last Updated: 2024-03-01
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
TERMINATED
Clinical Phase
NA
Total Enrollment
10 participants
Study Classification
INTERVENTIONAL
Study Start Date
2013-04-30
Study Completion Date
2014-06-25
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Primary objective:
Phase I Proof of concept: treatment with smaller doses of elemental calcium from ACC compared to CCS can maintain target serum calcium (corrected for albumin) values (7.0-10.0 mg/dL).
Phase II To test the hypothesis that treatment with smaller doses of elemental calcium from ACC compared to CCS can maintain target serum calcium (corrected for albumin) values (7.0-10.0 mg/dL).
Secondary objectives:
Phase I
* ACC dose selection - to confirm the conversion factor of ACC from CCS
* To determine the effect of food on ACC absorption
Phase II
* To test the hypothesis that treatment with smaller doses of elemental calcium from ACC compared to CCS will not cause an increase in hypercalciuria in patients with hypoparathyroidism
* To test the hypothesis that smaller doses of elemental calcium from ACC can reduce the side effects related with high calcium consumption.
Amorphical has a strong basis to believe that the ACC product is better absorbed compared to the commercially available CCS products and therefore, can maintain desirable target albumin corrected calcium values in serum (CA) with smaller doses of elemental calcium from ACC. As results, the burden of taking high doses of calcium supplementation along with the side effects of the standard therapy (gastrointestinal discomfort and hypercalciuria) will be reduced.
Testing serum CA and urine calcium values in subjects with hypoparathyroidism may provide a straightforward method to test this hypothesis.
The study is designed to be conducted with extra precaution in order to avoid disturbing the fragile balance between CA levels in serum and calcium levels urine. The crossover design of phase II of the study allows a more accurate and reliable comparison of results attributable to the specific treatment within the same individual. In addition, the subjects will continue consuming all their routine medication throughout the trial. The subjects in the control arm will consume their routine calcium supplement doses thus, will be treated with a standard of care.
Phase I Proof of concept: treatment with smaller doses of elemental calcium from ACC compared to CCS can maintain target serum calcium (corrected for albumin) values (7.0-10.0 mg/dL).
Phase II To test the hypothesis that treatment with smaller doses of elemental calcium from ACC compared to CCS can maintain target serum calcium (corrected for albumin) values (7.0-10.0 mg/dL).
Secondary objectives:
Phase I
* ACC dose selection - to confirm the conversion factor of ACC from CCS
* To determine the effect of food on ACC absorption
Phase II
* To test the hypothesis that treatment with smaller doses of elemental calcium from ACC compared to CCS will not cause an increase in hypercalciuria in patients with hypoparathyroidism
* To test the hypothesis that smaller doses of elemental calcium from ACC can reduce the side effects related with high calcium consumption.
Amorphical has a strong basis to believe that the ACC product is better absorbed compared to the commercially available CCS products and therefore, can maintain desirable target albumin corrected calcium values in serum (CA) with smaller doses of elemental calcium from ACC. As results, the burden of taking high doses of calcium supplementation along with the side effects of the standard therapy (gastrointestinal discomfort and hypercalciuria) will be reduced.
Testing serum CA and urine calcium values in subjects with hypoparathyroidism may provide a straightforward method to test this hypothesis.
The study is designed to be conducted with extra precaution in order to avoid disturbing the fragile balance between CA levels in serum and calcium levels urine. The crossover design of phase II of the study allows a more accurate and reliable comparison of results attributable to the specific treatment within the same individual. In addition, the subjects will continue consuming all their routine medication throughout the trial. The subjects in the control arm will consume their routine calcium supplement doses thus, will be treated with a standard of care.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study Comparing Amorphous Calcium Carbonate (ACC) Versus Crystalline Calcium CCS) in Hypoparathyroidism Patients
NCT01815021
Hypoparathyroidism
COMPLETED
PHASE1/PHASE2
A Study to Evaluate the Safety and Efficacy of Paricalcitol Capsules in Reducing Serum Intact Parathyroid Hormone Levels in End Stage Renal Disease Subjects on Peritoneal Dialysis
NCT00646035
End Stage Renal Disease
COMPLETED
PHASE3
Efficacy and Safety of Paricalcitol on the Treatment of Secondary Hyperparathyroidism in Calcitriol Resistant Dialysis Subjects
NCT00664430
Secondary Hyperparathyroidism
Dialysis
TERMINATED
PHASE4
Calcium and Phosphorus Balance and Calcium Kinetics in Patients With Stage 3/4 Chronic Kidney Disease
NCT01161407
Chronic Kidney Disease
COMPLETED
NA
Treatment of Secondary Hyperparathyroidism in the Uremic Patient
NCT00469599
Secondary Hyperparathyroidism
Chronic Kidney Disease
Vitamin D Deficiency
TERMINATED
NA
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Eligible subjects will be treated as follows:
Phase I Ten (10) subjects previously diagnosed and chronically treated for primary hypoparathyroidism will be enrolled. The daily CCS intake will be gradually replaced by reduced amount of elemental calcium from ACC. Five (5) subjects will consume the ACC before having a meal and the other five (5) subjects will consume the ACC after having a meal. The safety and the efficacy of the treatment will be closely monitored throughout this phase.
The absorption of ACC will be evaluated using weekly serum calcium corrected for albumin (CA) value tests. Excretion of calcium in urine will be tested at screening and at the end of phase I.
I-Day -21 (+/-17) Screening: Subjects with a diagnosed primary hypoparathyroidism (see section 4.1 for definitions), and who are treated with calcium and vitamin D supplementation at least 1 year prior to the beginning of the study and are without major renal or hepatic disease, will be invited to the Clinical Research Center. At the clinic, subjects will be interviewed, their medical history and their current medication will be documented and they will sign an informed consent form (ICF). Subjects will be referred to perform blood tests for serum calcium, P, creatinine and albumin levels. Calculation of albumin corrected calcium (CA) will be performed. Subjects will be instructed to perform 24 hour urine collection for Ca, P and creatinine. Subjects will be asked to fill out a food and medication diary for 3 consecutive days to evaluate their daily dietary calcium intake. Women of childbearing age will undergo a urine pregnancy test. Eligible subjects, complying with all inclusion criteria and having none of the exclusion criteria will be enrolled to the study.
Subjects will be informed by phone or on site whether they are eligible to enter the study.
I-Day 0: Eligible subjects will arrive at the Clinical Research Center where they will be asked about any changes in their medical condition since their last visit. Blood tests will be performed to define serum calcium, P and albumin baseline values. Calculation CA at baseline will be performed.
Subjects will receive a pack of ACC tablets, each tablet containing 50, 100 or 200 mg elemental calcium (according to the daily total amount of calcium supplementation, 14 day supply + 5 spare tablets). The replacement of CCS with ACC will be calculated according to the following formula:
NTDC = ITDC - \[0.1×ITDC (mg CCS)\] + \[0.05×ITDC (mg ACC)\]
\*ITDC - Initial total daily calcium intake (mg)
\*\*NTDC - New total daily calcium intake (mg)
10% (in mg) out of the initial total daily intake of elemental calcium will be replaced by 5% of elemental calcium from ACC (in mg, calculated out of the initial total daily intake). The daily intake of vitamin D will remain the same.
The calculation for the number of tablets per day will be performed specifically for each subject (according to the daily dosage of calcium supplementation) by the doctor.
Subjects will be instructed to take XXX ACC tablets a day, according to their individual calculated NTDC:
1. Five subjects will be instructed to take XXX tablets in the morning after a meal, XXX in midday after a meal and XXX in the evening after a meal.
2. Five subjects will be instructed to take XXX tablets in the morning before having a meal, XXX in midday before having a meal and XXX in the evening before having a meal.
Subjects will be instructed to continue their routine medications consumption during the trial.
I-Day 3 (±1): Subjects will arrive at the Clinical Research Center and their serum calcium, P and albumin levels will be tested. Calculation of CA will be performed to exclude hypocalcaemia (Ca\<7.0 mg/dL). If CA values are within the desired target range (7.0-10.0 mg/dl), subjects will continue to take the calcium doses that were instructed on I-day 0. If CA values are below 7.0 mg/dl or above 10.0 mg/dl, changes to the calcium intake will be made, according to the doctor's decision.
I-Day 7 (±1): Subjects will arrive at the Clinical Research Center and their serum calcium, P and albumin levels will be tested. Calculation of CA will be performed:
1. Conversion factor 0.5:
If CA = baseline, then 20% (in mg, calculated out of the initial total daily intake) of elemental calcium will be replaced by 10% of elemental calcium from ACC (in mg, calculated out of the initial total daily intake).
NTDC = ITDC - \[0.2×ITDC (mg CCS)\] + \[0.1×ITDC (mg ACC)\]
2. Conversion factor 0.75:
If CA \< baseline, then 10% (in mg, calculated out of the initial total daily intake) of elemental calcium will be replaced by 7.5% of elemental calcium from ACC (in mg, calculated out of the initial total daily intake).
NTDC = ITDC - \[0.1×ITDC (mg CCS)\] + \[0.075×ITDC (mg ACC)\] CA \<7.00 mg/dl will enforce end of treatment.
3. Conversion factor 0.25:
If CA \> baseline, then 10% (in mg, calculated out of the initial total daily intake) of elemental calcium will be replaced by 2.5% of elemental calcium from ACC (in mg, calculated out of the initial total daily intake).
NTDC = ITDC - \[0.1×ITDC (mg CCS)\] + \[0.025×ITDC (mg ACC)\] Subjects will be asked about any side effects or AEs that may have occurred and changes in concomitant medications since their last visit. Subjects will be asked about symptoms and signs related with a change in serum calcium levels (tetany, facial grimacing, paresthesias, muscle aches, arrhythmia, depression). Subjects will receive instructions regarding the new doses of ACC and will be reminded to take XXX tablets a day (according to their individual calculated NTDC), XXX in the morning, XXX in midday and XXX in the evening, before or after a meal (based on their initial assignment). Subjects will be reminded to continue their routine medications consumption during the trial.
I-Day 10 (±1): Subjects will arrive at the Clinical Research Center and their serum calcium, P and albumin levels will be tested. Calculation of CA will be performed to exclude hypocalcaemia (Ca\<7.0 mg/dL). If CA levels are within the desired target range (7.0-10.0 mg/dl), subjects will continue to take the calcium doses that were instructed on I-day 7. If CA levels are below 7.0 mg/dl or above 10.0 mg/dl, changes to the calcium intake will be made, according to the doctor's decision.
I-Day 14 (±1): Subjects will arrive at the Clinical Research Center and their serum calcium, P and albumin levels will be tested. Calculation of CA will be performed to exclude hypocalcaemia (Ca\<7.0 mg/dL). If none of the conversion formulas (a-c, I-Day 7) resulted in serum calcium values within the desired target range (7.0-10.0 mg/dL), the study will be terminated.
Subjects will be asked about any side effects or AEs that may have occurred and changes in concomitant medications since their last visit. Subjects will be asked about symptoms and signs related with a change in serum calcium levels (tetany, facial grimacing, paresthesias, muscle aches, arrhythmia, depression).
50% of the initial daily supplementation of CCS will be replaced by ACC based on the conversion factor found in I-day 7 (formulas a-c):
1. Conversion factor 0.5: 50% (in mg, calculated out of the initial total daily intake) of elemental calcium will be replaced by 25% of elemental calcium from ACC (in mg, calculated out of the initial total daily intake).
NTDC = ITDC - \[0.5×ITDC (mg CCS)\] + \[0.25×ITDC (mg ACC)\]
2. Conversion factor 0.75: 50% (in mg, calculated out of the initial total daily intake) of elemental calcium will be replaced by 37.5% of elemental calcium from ACC (in mg, calculated out of the initial total daily intake).
NTDC = ITDC - \[0.5×ITDC (mg CCS)\] + \[0.375×ITDC (mg ACC)\]
3. Conversion factor 0.25: 50% (in mg, calculated out of the initial total daily intake) of elemental calcium will be replaced by 12.5% of elemental calcium from ACC (in mg, calculated out of the initial total daily intake).
NTDC = ITDC - \[0.5×ITDC (mg CCS)\] + \[0.125×ITDC (mg ACC)\] Subjects will receive a pack of ACC tablets, each tablet containing 50, 100 or 200 mg elemental calcium (according to their individual calculated NTDC, 14 day supply + 5 spare tablets). Subjects will receive instructions regarding the new doses of ACC and will be reminded to take XXX capsules a day, XXX in the morning, XXX in midday and XXX in the evening, before or after a meal (based on their initial assignment). Subjects will be reminded to continue their routine medications consumption during the trial.
I-Day 21 (±1): Subjects will arrive at the Clinical Research Center and their serum calcium, P and albumin levels will be tested. Calculation of CA will be performed to exclude hypocalcaemia (Ca\<7.0 mg/dL). Subjects will be asked about any side effects or AEs that may have occurred and changes in concomitant medications since their last visit. Subjects will be asked about symptoms and signs related with a change in serum calcium levels (tetany, facial grimacing, paresthesias, muscle aches, arrhythmia, depression). If CA levels are below 7.0 mg/dl, or above 10.0 mg/dl, subject will be excluded from the study (based on the doctor's decision). If CA levels are within the desired target range (7.0-10.0 mg/dL), a complete replacement of the daily supplementation of CCS with ACC will be performed, based on the conversion factor found in I-day 7 (formulas a-c):
1. Conversion factor 0.5: 100% (in mg) of the elemental calcium initial total daily intake will be replaced by 50% of elemental calcium from ACC (in mg, calculated out of the initial total daily intake).
NTDC = ITDC - \[ITDC (mg CCS)\] + \[0.5×ITDC (mg ACC)\]
2. Conversion factor 0.75: 100% (in mg) of the elemental calcium initial total daily intake will be replaced by 75% of elemental calcium from ACC (in mg, calculated out of the initial total daily intake).
NTDC = ITDC - \[ITDC (mg CCS)\] + \[0. 75×ITDC (mg ACC)\]
3. Conversion factor 0.25: 100% (in mg) of the elemental calcium initial total daily intake will be replaced by 25% of elemental calcium from ACC (in mg, calculated out of the initial total daily intake).
NTDC = ITDC - \[ITDC (mg CCS)\] + \[0.25×ITDC (mg ACC)\] Subjects will receive instructions regarding the new doses of ACC and will be reminded to take XXX tablets a day, XXX in the morning, XXX in midday and XXX in the evening, before or after a meal (based on their initial assignment). Subjects will be reminded to continue their routine medications consumption during the trial.
Subjects will receive a container to perform 24 hour urine collection prior to their next scheduled visit.
I-Day 27 (±1) by phone: Subjects will be reminded to perform 24 hour urine collection.
I-Day 28 (±1) - Termination of phase I: Subjects will arrive at the Clinical Research Center and their serum calcium, P and albumin levels will be tested. Calculation of CA will be performed. Subjects will provide the container of 24 hour urine collection for Ca, P and creatinine to test calciuria. Subjects will be asked about any side effects or AEs that may have occurred and changes in concomitant medications since their last visit. Subjects will be asked about symptoms and signs related with a change in serum calcium levels (tetany, facial grimacing, paresthesias, muscle aches, arrhythmia, depression).
Phase I results will be examined before deciding whether or not to embark on the crossover portion of the study planned for Phase II. Phase I data will be summarized, showing for each subject, by arm and overall the relationship between CA levels by amount of ACC replacement of CCS received.
Phase II Ten (10) subjects previously diagnosed and chronically treated for primary hypoparathyroidism will be enrolled. Subjects participated in phase I will be offered to participate in phase II as well. If needed, new subjects will be enrolled.
The subjects will be randomly assigned to one of the following treatments for 6 weeks:
1. Standard of care (CCS) - The same elemental calcium dosage that was used routinely prior to the study.
2. ACC - The established dosage of elemental calcium from ACC (based on the conversion factor and the fed/fasted conditions found in phase I of the study).
The two formulations will be administered with the regular daily dosage of vitamin D (1-alfa D3).
At the end of the treatment, each group will receive the alternative formulation for another 6 weeks.
The superior absorption of ACC will be evaluated using weekly blood tests to calculate serum CA values. Excretion of calcium in urine will be tested at screening and in the end of each treatment.
II-Day -21 (+/-17) Screening: Subjects with a diagnosed primary hypoparathyroidism (see section 4.1 for definitions), and who receiving calcium and vitamin D supplementation at least 1 year prior to the beginning of the study and are without major renal or hepatic disease, will be invited to the Clinical Research Center . At the clinic, subjects will be interviewed, their medical history and their current medication will be documented and they will sign an informed consent form (ICF). Subjects will be referred to perform blood tests for Calcium, P and albumin levels. Calculation of CA will be performed. Subjects will be instructed to perform 24 hour urine collection for Ca, P and creatinine levels. Subjects will be asked to fill out a food and medication diary for 3 consecutive days to evaluate their daily dietary calcium intake. Women of childbearing age will undergo a urine pregnancy test. Eligible subjects, complying with all inclusion criteria and having none of the exclusion criteria will be enrolled to the study.
Subjects will be informed by phone or on site whether they are eligible to enter the study.
II-Day 0: Eligible subjects will arrive at the Clinical Research Center where they will be asked about any changes in their medical condition since their last visit. Blood tests will be performed to define serum calcium, P and albumin baseline values. CA values will be calculated at baseline.
Subjects will be randomly assigned to one of the following treatments:
1. Standard-of-care (CCS) - The same elemental calcium dosage that was used routinely prior to the study.
2. ACC - The established dosage of elemental calcium from ACC (based on the conversion factor and the fed/fasted conditions found in phase I of the study).
Subjects that were assigned to the ACC treatment arm, will receive a pack of ACC tablets, each tablet containing 200 mg elemental calcium (35 day supply + 5 spare tablets). Subjects assigned to the CCS treatment arm will continue to take their routine calcium supplementation.
The exact dosage of calcium supplementation will be determined for each subject according the known medical history.
Subjects will be instructed to continue their routine medications consumption during the trial.
II-Day 3 (±1): Subjects will arrive at the Clinical Research Center and their serum calcium, P and albumin levels will be tested. Calculation of CA will be performed to exclude hypocalcaemia (Ca\<7.0 mg/dL). If CA values are within the desired target range (7.0-10.0 mg/dl), subjects will continue to take the calcium doses that were instructed on II-day 0. If CA levels are below 7.0 mg/dL or above 10.0 mg/dL, changes to calcium intake will be made, according to the doctor's decision
II-Day 7 (±1): Subjects will arrive at the Clinical Research Center and their serum calcium, P and albumin levels will be tested. Calculation of CA will be performed. Subjects will be asked about any side effects or AEs that may have occurred and changes in concomitant medications since their last visit. Subjects will be asked about symptoms and signs related with a change in serum calcium levels (tetany, facial grimacing, paresthesias, muscle aches, arrhythmia, depression). Adjustments of ACC or CCS intake will be performed if necessary.
Subjects will be reminded to take the calcium supplementation according to their assignment instructions.
Subjects will be reminded to continue their routine medications consumption during the trial.
II-Day 10 (±1): Subjects will arrive at the Clinical Research Center and their serum calcium, P and albumin levels will be tested. Calculation of CA will be performed to exclude hypocalcaemia (Ca\<7.0 mg/dL). If CA levels are within the desired target range (7.0-10.0 mg/dl), subjects will continue to take the calcium doses that were instructed on II-day 7. If CA levels are below 7.0 mg/dL, or above 10.0 mg/dL, changes to the calcium intake will be made, according to the doctor's decision
II-Day 14 (±1): Subjects will arrive at the Clinical Research Center and their serum calcium, P and albumin levels will be tested. Calculation of CA will be performed. Subjects will be asked about any side effects or AEs that may have occurred and changes in concomitant medications since their last visit. Subjects will be asked about symptoms and signs related with a change in serum calcium levels (tetany, facial grimacing, paresthesias, muscle aches, arrhythmia, depression).
Subjects will be reminded to take the calcium supplementation according to their assignment instructions.
Subjects will be reminded to continue their routine medications consumption during the trial.
II-Day 21 (±1): Subjects will arrive at the Clinical Research Center and their serum calcium, P and albumin will be tested. Calculation of CA will be performed. Subjects will be asked about any side effects or AEs that may have occurred and changes in concomitant medications since their last visit. Subjects will be asked about symptoms and signs related with a change in serum calcium levels (tetany, facial grimacing, paresthesias, muscle aches, arrhythmia, depression).
Subjects will be reminded to take the calcium supplementation according to the instructions.
Subjects will be reminded to continue their routine medications consumption during the trial.
Subjects will receive a container to perform 24 hour urine collection prior to their next scheduled visit.
II-Day 34 (±1) by phone: Subjects will be reminded to perform 24 hour urine collection.
II-Day 35 (±1): Subjects will arrive to the Clinical Research Center and their serum calcium, P and albumin levels will be tested. Calculation of CA will be performed. Subjects will provide the container with 24 hour urine collection for Ca, P and creatinine to test calciuria. Subjects will be asked about any side effects or AEs that may have occurred and changes in concomitant medications since their last visit. Subjects will be asked about symptoms and signs related with a change in serum calcium levels (tetany, facial grimacing, paresthesias, muscle aches, arrhythmia, depression).
Subjects previously assigned to the CCS treatment arm will receive a pack of ACC tablets, each tablet containing 200 mg elemental calcium (35 day supply + 5 spare tablets). Subjects previously assigned to the ACC treatment arm, will be instructed to resume their regular CCS supplementation.
The exact dosage of calcium supplementation for each subject will be determined by the known medical history.
Subjects will be reminded to continue their routine medications consumption during the trial.
II-Day 38 (±1): Subjects will arrive at the Clinical Research Center and their serum calcium, P and albumin levels will be tested. Calculation of CA will be performed to exclude hypocalcaemia (Ca\<7.0 mg/dL). If CA levels are within the desired target range (7.0-10.0 mg/dl), subjects will continue to take the calcium doses that were instructed on II-day 35. If CA levels are below 7.0 mg/dl or above 10.0 mg/dl, changes to the calcium intake will be made, according to the doctor's decision
II-Day 42 (±1): Subjects will arrive at the Clinical Research Center and their serum calcium, P and albumin levels will be tested. Calculation of CA will be performed. Subjects will be asked about any side effects or AEs that may have occurred and changes in concomitant medications since their last visit. Subjects will be asked about symptoms and signs related with a change in serum calcium levels (tetany, facial grimacing, paresthesias, muscle aches, arrhythmia, depression). Adjustments of ACC or CCS intake will be performed if necessary.
Subjects will be reminded to take the calcium supplementation according to their assignment instructions.
Subjects will be reminded to continue their routine medications consumption during the trial.
II-Day 45 (±1): Subjects will arrive at the Clinical Research Center and their serum calcium, P and albumin levels will be tested. Calculation of CA will be performed to exclude hypocalcaemia (Ca\<7.0 mg/dL). If CA levels are within the desired target range (7.0-10.0 mg/dl), subjects will continue to take the calcium doses that were instructed on II-day 42. If CA levels are below 7.0 mg/dl or above 10.0 mg/dl, changes to the calcium intake will be made, according to the doctor's decision
II-Day 49 (±1): Subjects will arrive at the Clinical Research Center and their serum calcium, P and albumin levels will be tested. Calculation of CA will be performed. Subjects will be asked about any side effects or AEs that may have occurred and changes in concomitant medications since their last visit. Subjects will be asked about symptoms and signs related with a change in serum calcium levels (tetany, facial grimacing, paresthesias, muscle aches, arrhythmia, depression).
Subjects will be reminded to take the calcium supplementation according to their assignment instructions.
Subjects will be reminded to continue their routine medications consumption during the trial.
II-Day 56 (±1): Subjects will arrive at the Clinical Research Center and their serum calcium, P and albumin levels will be tested. Calculation of CA will be performed. Subjects will be asked about any side effects or AEs that may have occurred and changes in concomitant medications since their last visit. Subjects will be asked about symptoms and signs related with a change in serum calcium levels (tetany, facial grimacing, paresthesias, muscle aches, arrhythmia, depression).
Subjects will be reminded to take the calcium supplementation according to their assignment instructions.
Subjects will be reminded to continue their routine medications consumption during the trial.
Subjects will receive a container to perform 24 hour urine collection prior to their next scheduled visit.
II-Day 69 (±1) by phone: Subjects will be reminded to perform 24 hour urine collection.
II-Day 70 (±1) - Termination of phase II: Subjects will arrive at the Clinical Research Center and their serum calcium, P and albumin levels will be tested. Calculation of CA will be performed. Subjects will provide the container with 24 hour urine collection for Ca, P and creatinine to test calciuria. Subjects will be asked about any side effects or AEs that may have occurred and changes in concomitant medications since their last visit. Subjects will be asked about symptoms and signs related with a change in serum calcium levels (tetany, facial grimacing, paresthesias, muscle aches, arrhythmia, depression).
Phase I Ten (10) subjects previously diagnosed and chronically treated for primary hypoparathyroidism will be enrolled. The daily CCS intake will be gradually replaced by reduced amount of elemental calcium from ACC. Five (5) subjects will consume the ACC before having a meal and the other five (5) subjects will consume the ACC after having a meal. The safety and the efficacy of the treatment will be closely monitored throughout this phase.
The absorption of ACC will be evaluated using weekly serum calcium corrected for albumin (CA) value tests. Excretion of calcium in urine will be tested at screening and at the end of phase I.
I-Day -21 (+/-17) Screening: Subjects with a diagnosed primary hypoparathyroidism (see section 4.1 for definitions), and who are treated with calcium and vitamin D supplementation at least 1 year prior to the beginning of the study and are without major renal or hepatic disease, will be invited to the Clinical Research Center. At the clinic, subjects will be interviewed, their medical history and their current medication will be documented and they will sign an informed consent form (ICF). Subjects will be referred to perform blood tests for serum calcium, P, creatinine and albumin levels. Calculation of albumin corrected calcium (CA) will be performed. Subjects will be instructed to perform 24 hour urine collection for Ca, P and creatinine. Subjects will be asked to fill out a food and medication diary for 3 consecutive days to evaluate their daily dietary calcium intake. Women of childbearing age will undergo a urine pregnancy test. Eligible subjects, complying with all inclusion criteria and having none of the exclusion criteria will be enrolled to the study.
Subjects will be informed by phone or on site whether they are eligible to enter the study.
I-Day 0: Eligible subjects will arrive at the Clinical Research Center where they will be asked about any changes in their medical condition since their last visit. Blood tests will be performed to define serum calcium, P and albumin baseline values. Calculation CA at baseline will be performed.
Subjects will receive a pack of ACC tablets, each tablet containing 50, 100 or 200 mg elemental calcium (according to the daily total amount of calcium supplementation, 14 day supply + 5 spare tablets). The replacement of CCS with ACC will be calculated according to the following formula:
NTDC = ITDC - \[0.1×ITDC (mg CCS)\] + \[0.05×ITDC (mg ACC)\]
\*ITDC - Initial total daily calcium intake (mg)
\*\*NTDC - New total daily calcium intake (mg)
10% (in mg) out of the initial total daily intake of elemental calcium will be replaced by 5% of elemental calcium from ACC (in mg, calculated out of the initial total daily intake). The daily intake of vitamin D will remain the same.
The calculation for the number of tablets per day will be performed specifically for each subject (according to the daily dosage of calcium supplementation) by the doctor.
Subjects will be instructed to take XXX ACC tablets a day, according to their individual calculated NTDC:
1. Five subjects will be instructed to take XXX tablets in the morning after a meal, XXX in midday after a meal and XXX in the evening after a meal.
2. Five subjects will be instructed to take XXX tablets in the morning before having a meal, XXX in midday before having a meal and XXX in the evening before having a meal.
Subjects will be instructed to continue their routine medications consumption during the trial.
I-Day 3 (±1): Subjects will arrive at the Clinical Research Center and their serum calcium, P and albumin levels will be tested. Calculation of CA will be performed to exclude hypocalcaemia (Ca\<7.0 mg/dL). If CA values are within the desired target range (7.0-10.0 mg/dl), subjects will continue to take the calcium doses that were instructed on I-day 0. If CA values are below 7.0 mg/dl or above 10.0 mg/dl, changes to the calcium intake will be made, according to the doctor's decision.
I-Day 7 (±1): Subjects will arrive at the Clinical Research Center and their serum calcium, P and albumin levels will be tested. Calculation of CA will be performed:
1. Conversion factor 0.5:
If CA = baseline, then 20% (in mg, calculated out of the initial total daily intake) of elemental calcium will be replaced by 10% of elemental calcium from ACC (in mg, calculated out of the initial total daily intake).
NTDC = ITDC - \[0.2×ITDC (mg CCS)\] + \[0.1×ITDC (mg ACC)\]
2. Conversion factor 0.75:
If CA \< baseline, then 10% (in mg, calculated out of the initial total daily intake) of elemental calcium will be replaced by 7.5% of elemental calcium from ACC (in mg, calculated out of the initial total daily intake).
NTDC = ITDC - \[0.1×ITDC (mg CCS)\] + \[0.075×ITDC (mg ACC)\] CA \<7.00 mg/dl will enforce end of treatment.
3. Conversion factor 0.25:
If CA \> baseline, then 10% (in mg, calculated out of the initial total daily intake) of elemental calcium will be replaced by 2.5% of elemental calcium from ACC (in mg, calculated out of the initial total daily intake).
NTDC = ITDC - \[0.1×ITDC (mg CCS)\] + \[0.025×ITDC (mg ACC)\] Subjects will be asked about any side effects or AEs that may have occurred and changes in concomitant medications since their last visit. Subjects will be asked about symptoms and signs related with a change in serum calcium levels (tetany, facial grimacing, paresthesias, muscle aches, arrhythmia, depression). Subjects will receive instructions regarding the new doses of ACC and will be reminded to take XXX tablets a day (according to their individual calculated NTDC), XXX in the morning, XXX in midday and XXX in the evening, before or after a meal (based on their initial assignment). Subjects will be reminded to continue their routine medications consumption during the trial.
I-Day 10 (±1): Subjects will arrive at the Clinical Research Center and their serum calcium, P and albumin levels will be tested. Calculation of CA will be performed to exclude hypocalcaemia (Ca\<7.0 mg/dL). If CA levels are within the desired target range (7.0-10.0 mg/dl), subjects will continue to take the calcium doses that were instructed on I-day 7. If CA levels are below 7.0 mg/dl or above 10.0 mg/dl, changes to the calcium intake will be made, according to the doctor's decision.
I-Day 14 (±1): Subjects will arrive at the Clinical Research Center and their serum calcium, P and albumin levels will be tested. Calculation of CA will be performed to exclude hypocalcaemia (Ca\<7.0 mg/dL). If none of the conversion formulas (a-c, I-Day 7) resulted in serum calcium values within the desired target range (7.0-10.0 mg/dL), the study will be terminated.
Subjects will be asked about any side effects or AEs that may have occurred and changes in concomitant medications since their last visit. Subjects will be asked about symptoms and signs related with a change in serum calcium levels (tetany, facial grimacing, paresthesias, muscle aches, arrhythmia, depression).
50% of the initial daily supplementation of CCS will be replaced by ACC based on the conversion factor found in I-day 7 (formulas a-c):
1. Conversion factor 0.5: 50% (in mg, calculated out of the initial total daily intake) of elemental calcium will be replaced by 25% of elemental calcium from ACC (in mg, calculated out of the initial total daily intake).
NTDC = ITDC - \[0.5×ITDC (mg CCS)\] + \[0.25×ITDC (mg ACC)\]
2. Conversion factor 0.75: 50% (in mg, calculated out of the initial total daily intake) of elemental calcium will be replaced by 37.5% of elemental calcium from ACC (in mg, calculated out of the initial total daily intake).
NTDC = ITDC - \[0.5×ITDC (mg CCS)\] + \[0.375×ITDC (mg ACC)\]
3. Conversion factor 0.25: 50% (in mg, calculated out of the initial total daily intake) of elemental calcium will be replaced by 12.5% of elemental calcium from ACC (in mg, calculated out of the initial total daily intake).
NTDC = ITDC - \[0.5×ITDC (mg CCS)\] + \[0.125×ITDC (mg ACC)\] Subjects will receive a pack of ACC tablets, each tablet containing 50, 100 or 200 mg elemental calcium (according to their individual calculated NTDC, 14 day supply + 5 spare tablets). Subjects will receive instructions regarding the new doses of ACC and will be reminded to take XXX capsules a day, XXX in the morning, XXX in midday and XXX in the evening, before or after a meal (based on their initial assignment). Subjects will be reminded to continue their routine medications consumption during the trial.
I-Day 21 (±1): Subjects will arrive at the Clinical Research Center and their serum calcium, P and albumin levels will be tested. Calculation of CA will be performed to exclude hypocalcaemia (Ca\<7.0 mg/dL). Subjects will be asked about any side effects or AEs that may have occurred and changes in concomitant medications since their last visit. Subjects will be asked about symptoms and signs related with a change in serum calcium levels (tetany, facial grimacing, paresthesias, muscle aches, arrhythmia, depression). If CA levels are below 7.0 mg/dl, or above 10.0 mg/dl, subject will be excluded from the study (based on the doctor's decision). If CA levels are within the desired target range (7.0-10.0 mg/dL), a complete replacement of the daily supplementation of CCS with ACC will be performed, based on the conversion factor found in I-day 7 (formulas a-c):
1. Conversion factor 0.5: 100% (in mg) of the elemental calcium initial total daily intake will be replaced by 50% of elemental calcium from ACC (in mg, calculated out of the initial total daily intake).
NTDC = ITDC - \[ITDC (mg CCS)\] + \[0.5×ITDC (mg ACC)\]
2. Conversion factor 0.75: 100% (in mg) of the elemental calcium initial total daily intake will be replaced by 75% of elemental calcium from ACC (in mg, calculated out of the initial total daily intake).
NTDC = ITDC - \[ITDC (mg CCS)\] + \[0. 75×ITDC (mg ACC)\]
3. Conversion factor 0.25: 100% (in mg) of the elemental calcium initial total daily intake will be replaced by 25% of elemental calcium from ACC (in mg, calculated out of the initial total daily intake).
NTDC = ITDC - \[ITDC (mg CCS)\] + \[0.25×ITDC (mg ACC)\] Subjects will receive instructions regarding the new doses of ACC and will be reminded to take XXX tablets a day, XXX in the morning, XXX in midday and XXX in the evening, before or after a meal (based on their initial assignment). Subjects will be reminded to continue their routine medications consumption during the trial.
Subjects will receive a container to perform 24 hour urine collection prior to their next scheduled visit.
I-Day 27 (±1) by phone: Subjects will be reminded to perform 24 hour urine collection.
I-Day 28 (±1) - Termination of phase I: Subjects will arrive at the Clinical Research Center and their serum calcium, P and albumin levels will be tested. Calculation of CA will be performed. Subjects will provide the container of 24 hour urine collection for Ca, P and creatinine to test calciuria. Subjects will be asked about any side effects or AEs that may have occurred and changes in concomitant medications since their last visit. Subjects will be asked about symptoms and signs related with a change in serum calcium levels (tetany, facial grimacing, paresthesias, muscle aches, arrhythmia, depression).
Phase I results will be examined before deciding whether or not to embark on the crossover portion of the study planned for Phase II. Phase I data will be summarized, showing for each subject, by arm and overall the relationship between CA levels by amount of ACC replacement of CCS received.
Phase II Ten (10) subjects previously diagnosed and chronically treated for primary hypoparathyroidism will be enrolled. Subjects participated in phase I will be offered to participate in phase II as well. If needed, new subjects will be enrolled.
The subjects will be randomly assigned to one of the following treatments for 6 weeks:
1. Standard of care (CCS) - The same elemental calcium dosage that was used routinely prior to the study.
2. ACC - The established dosage of elemental calcium from ACC (based on the conversion factor and the fed/fasted conditions found in phase I of the study).
The two formulations will be administered with the regular daily dosage of vitamin D (1-alfa D3).
At the end of the treatment, each group will receive the alternative formulation for another 6 weeks.
The superior absorption of ACC will be evaluated using weekly blood tests to calculate serum CA values. Excretion of calcium in urine will be tested at screening and in the end of each treatment.
II-Day -21 (+/-17) Screening: Subjects with a diagnosed primary hypoparathyroidism (see section 4.1 for definitions), and who receiving calcium and vitamin D supplementation at least 1 year prior to the beginning of the study and are without major renal or hepatic disease, will be invited to the Clinical Research Center . At the clinic, subjects will be interviewed, their medical history and their current medication will be documented and they will sign an informed consent form (ICF). Subjects will be referred to perform blood tests for Calcium, P and albumin levels. Calculation of CA will be performed. Subjects will be instructed to perform 24 hour urine collection for Ca, P and creatinine levels. Subjects will be asked to fill out a food and medication diary for 3 consecutive days to evaluate their daily dietary calcium intake. Women of childbearing age will undergo a urine pregnancy test. Eligible subjects, complying with all inclusion criteria and having none of the exclusion criteria will be enrolled to the study.
Subjects will be informed by phone or on site whether they are eligible to enter the study.
II-Day 0: Eligible subjects will arrive at the Clinical Research Center where they will be asked about any changes in their medical condition since their last visit. Blood tests will be performed to define serum calcium, P and albumin baseline values. CA values will be calculated at baseline.
Subjects will be randomly assigned to one of the following treatments:
1. Standard-of-care (CCS) - The same elemental calcium dosage that was used routinely prior to the study.
2. ACC - The established dosage of elemental calcium from ACC (based on the conversion factor and the fed/fasted conditions found in phase I of the study).
Subjects that were assigned to the ACC treatment arm, will receive a pack of ACC tablets, each tablet containing 200 mg elemental calcium (35 day supply + 5 spare tablets). Subjects assigned to the CCS treatment arm will continue to take their routine calcium supplementation.
The exact dosage of calcium supplementation will be determined for each subject according the known medical history.
Subjects will be instructed to continue their routine medications consumption during the trial.
II-Day 3 (±1): Subjects will arrive at the Clinical Research Center and their serum calcium, P and albumin levels will be tested. Calculation of CA will be performed to exclude hypocalcaemia (Ca\<7.0 mg/dL). If CA values are within the desired target range (7.0-10.0 mg/dl), subjects will continue to take the calcium doses that were instructed on II-day 0. If CA levels are below 7.0 mg/dL or above 10.0 mg/dL, changes to calcium intake will be made, according to the doctor's decision
II-Day 7 (±1): Subjects will arrive at the Clinical Research Center and their serum calcium, P and albumin levels will be tested. Calculation of CA will be performed. Subjects will be asked about any side effects or AEs that may have occurred and changes in concomitant medications since their last visit. Subjects will be asked about symptoms and signs related with a change in serum calcium levels (tetany, facial grimacing, paresthesias, muscle aches, arrhythmia, depression). Adjustments of ACC or CCS intake will be performed if necessary.
Subjects will be reminded to take the calcium supplementation according to their assignment instructions.
Subjects will be reminded to continue their routine medications consumption during the trial.
II-Day 10 (±1): Subjects will arrive at the Clinical Research Center and their serum calcium, P and albumin levels will be tested. Calculation of CA will be performed to exclude hypocalcaemia (Ca\<7.0 mg/dL). If CA levels are within the desired target range (7.0-10.0 mg/dl), subjects will continue to take the calcium doses that were instructed on II-day 7. If CA levels are below 7.0 mg/dL, or above 10.0 mg/dL, changes to the calcium intake will be made, according to the doctor's decision
II-Day 14 (±1): Subjects will arrive at the Clinical Research Center and their serum calcium, P and albumin levels will be tested. Calculation of CA will be performed. Subjects will be asked about any side effects or AEs that may have occurred and changes in concomitant medications since their last visit. Subjects will be asked about symptoms and signs related with a change in serum calcium levels (tetany, facial grimacing, paresthesias, muscle aches, arrhythmia, depression).
Subjects will be reminded to take the calcium supplementation according to their assignment instructions.
Subjects will be reminded to continue their routine medications consumption during the trial.
II-Day 21 (±1): Subjects will arrive at the Clinical Research Center and their serum calcium, P and albumin will be tested. Calculation of CA will be performed. Subjects will be asked about any side effects or AEs that may have occurred and changes in concomitant medications since their last visit. Subjects will be asked about symptoms and signs related with a change in serum calcium levels (tetany, facial grimacing, paresthesias, muscle aches, arrhythmia, depression).
Subjects will be reminded to take the calcium supplementation according to the instructions.
Subjects will be reminded to continue their routine medications consumption during the trial.
Subjects will receive a container to perform 24 hour urine collection prior to their next scheduled visit.
II-Day 34 (±1) by phone: Subjects will be reminded to perform 24 hour urine collection.
II-Day 35 (±1): Subjects will arrive to the Clinical Research Center and their serum calcium, P and albumin levels will be tested. Calculation of CA will be performed. Subjects will provide the container with 24 hour urine collection for Ca, P and creatinine to test calciuria. Subjects will be asked about any side effects or AEs that may have occurred and changes in concomitant medications since their last visit. Subjects will be asked about symptoms and signs related with a change in serum calcium levels (tetany, facial grimacing, paresthesias, muscle aches, arrhythmia, depression).
Subjects previously assigned to the CCS treatment arm will receive a pack of ACC tablets, each tablet containing 200 mg elemental calcium (35 day supply + 5 spare tablets). Subjects previously assigned to the ACC treatment arm, will be instructed to resume their regular CCS supplementation.
The exact dosage of calcium supplementation for each subject will be determined by the known medical history.
Subjects will be reminded to continue their routine medications consumption during the trial.
II-Day 38 (±1): Subjects will arrive at the Clinical Research Center and their serum calcium, P and albumin levels will be tested. Calculation of CA will be performed to exclude hypocalcaemia (Ca\<7.0 mg/dL). If CA levels are within the desired target range (7.0-10.0 mg/dl), subjects will continue to take the calcium doses that were instructed on II-day 35. If CA levels are below 7.0 mg/dl or above 10.0 mg/dl, changes to the calcium intake will be made, according to the doctor's decision
II-Day 42 (±1): Subjects will arrive at the Clinical Research Center and their serum calcium, P and albumin levels will be tested. Calculation of CA will be performed. Subjects will be asked about any side effects or AEs that may have occurred and changes in concomitant medications since their last visit. Subjects will be asked about symptoms and signs related with a change in serum calcium levels (tetany, facial grimacing, paresthesias, muscle aches, arrhythmia, depression). Adjustments of ACC or CCS intake will be performed if necessary.
Subjects will be reminded to take the calcium supplementation according to their assignment instructions.
Subjects will be reminded to continue their routine medications consumption during the trial.
II-Day 45 (±1): Subjects will arrive at the Clinical Research Center and their serum calcium, P and albumin levels will be tested. Calculation of CA will be performed to exclude hypocalcaemia (Ca\<7.0 mg/dL). If CA levels are within the desired target range (7.0-10.0 mg/dl), subjects will continue to take the calcium doses that were instructed on II-day 42. If CA levels are below 7.0 mg/dl or above 10.0 mg/dl, changes to the calcium intake will be made, according to the doctor's decision
II-Day 49 (±1): Subjects will arrive at the Clinical Research Center and their serum calcium, P and albumin levels will be tested. Calculation of CA will be performed. Subjects will be asked about any side effects or AEs that may have occurred and changes in concomitant medications since their last visit. Subjects will be asked about symptoms and signs related with a change in serum calcium levels (tetany, facial grimacing, paresthesias, muscle aches, arrhythmia, depression).
Subjects will be reminded to take the calcium supplementation according to their assignment instructions.
Subjects will be reminded to continue their routine medications consumption during the trial.
II-Day 56 (±1): Subjects will arrive at the Clinical Research Center and their serum calcium, P and albumin levels will be tested. Calculation of CA will be performed. Subjects will be asked about any side effects or AEs that may have occurred and changes in concomitant medications since their last visit. Subjects will be asked about symptoms and signs related with a change in serum calcium levels (tetany, facial grimacing, paresthesias, muscle aches, arrhythmia, depression).
Subjects will be reminded to take the calcium supplementation according to their assignment instructions.
Subjects will be reminded to continue their routine medications consumption during the trial.
Subjects will receive a container to perform 24 hour urine collection prior to their next scheduled visit.
II-Day 69 (±1) by phone: Subjects will be reminded to perform 24 hour urine collection.
II-Day 70 (±1) - Termination of phase II: Subjects will arrive at the Clinical Research Center and their serum calcium, P and albumin levels will be tested. Calculation of CA will be performed. Subjects will provide the container with 24 hour urine collection for Ca, P and creatinine to test calciuria. Subjects will be asked about any side effects or AEs that may have occurred and changes in concomitant medications since their last visit. Subjects will be asked about symptoms and signs related with a change in serum calcium levels (tetany, facial grimacing, paresthesias, muscle aches, arrhythmia, depression).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Hypoparathyroidism
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NA
Intervention Model
SINGLE_GROUP
Proof of concept: treatment with smaller doses of elemental calcium from ACC compared to CCS can maintain target serum calcium (corrected for albumin) values (7.0-10.0 mg/dL)
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
amorphous calcium carbonate
Ten (10) subjects previously diagnosed and chronically treated for primary hypoparathyroidism will be enrolled. The daily CCS intake will be gradually replaced by reduced amount of elemental calcium from ACC. Five (5) subjects will consume the ACC before having a meal and the other five (5) subjects will consume the ACC after having a meal. The safety and the efficacy of the treatment will be closely monitored throughout this phase.
Group Type
EXPERIMENTAL
amorphous calcium carbonate
Intervention Type
DIETARY_SUPPLEMENT
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
amorphous calcium carbonate
Intervention Type
DIETARY_SUPPLEMENT
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
ACC
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Primary Hypoparathyroidism - low levels of intact PTH during hypocalcemia at diagnosis.
* Subjects receiving calcium and vitamin D supplementation at least 1 year prior to the beginning of the study.
* Subjects able to adhere to the visit schedule and protocol requirements and be available to complete the study.
* Subjects who provide written informed consent to participate in the study.
* Age: 18-80, inclusive.
* Subjects receiving calcium and vitamin D supplementation at least 1 year prior to the beginning of the study.
* Subjects able to adhere to the visit schedule and protocol requirements and be available to complete the study.
* Subjects who provide written informed consent to participate in the study.
* Age: 18-80, inclusive.
Exclusion Criteria
* Calcium (albumin corrected) serum values below 7.0 mg/dL or above 10.0 mg/dL
* Any known diseases affecting the absorption from the gastrointestinal tract:
* Inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis)
* Chronic diarrhea
* Subjects with neuropsychiatric disease.
* Subjects with impaired renal function (glomerular filtration rate, ≤40 mL/min)
* Subjects with other severe chronic disease requiring long-term therapy.
* Impaired liver function (Liver enzymes\> x3 upper limit of normal).
* Subjects with history or presence of kidney stones
* Recurrent urinary tract infections
* Subjects taking drugs which might affect calcium levels such as:
* Fusid
* Anticonvulsants
* Carbonic anhydrase
* Adrenocorticosteroids
* Subjects who are non-cooperative or unwilling to sign consent form.
* Pregnant or breast-feeding women.
* Any known diseases affecting the absorption from the gastrointestinal tract:
* Inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis)
* Chronic diarrhea
* Subjects with neuropsychiatric disease.
* Subjects with impaired renal function (glomerular filtration rate, ≤40 mL/min)
* Subjects with other severe chronic disease requiring long-term therapy.
* Impaired liver function (Liver enzymes\> x3 upper limit of normal).
* Subjects with history or presence of kidney stones
* Recurrent urinary tract infections
* Subjects taking drugs which might affect calcium levels such as:
* Fusid
* Anticonvulsants
* Carbonic anhydrase
* Adrenocorticosteroids
* Subjects who are non-cooperative or unwilling to sign consent form.
* Pregnant or breast-feeding women.
Minimum Eligible Age
18 Years
Maximum Eligible Age
80 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Amorphical Ltd.
INDUSTRY
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Sophia Ish-Shalom, MD
Role: PRINCIPAL_INVESTIGATOR
Dity Natan, McS
Role: STUDY_DIRECTOR
Amorphical Ltd.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Rambam Health Care Campus
Haifa, , Israel
Site Status
Countries
Review the countries where the study has at least one active or historical site.
Israel
References
Explore related publications, articles, or registry entries linked to this study.
Brandi ML, Bilezikian JP, Shoback D, Bouillon R, Clarke BL, Thakker RV, Khan AA, Potts JT Jr. Management of Hypoparathyroidism: Summary Statement and Guidelines. J Clin Endocrinol Metab. 2016 Jun;101(6):2273-83. doi: 10.1210/jc.2015-3907. Epub 2016 Mar 4.
Reference Type
BACKGROUND
Bilezikian JP, Matsumoto T, Bellido T, Khosla S, Martin J, Recker RR, Heaney R, Seeman E, Papapoulos S, Goldring SR. Targeting bone remodeling for the treatment of osteoporosis: summary of the proceedings of an ASBMR workshop. J Bone Miner Res. 2009 Mar;24(3):373-85. doi: 10.1359/jbmr.090105. No abstract available.
Reference Type
BACKGROUND
Rubin MR, Dempster DW, Kohler T, Stauber M, Zhou H, Shane E, Nickolas T, Stein E, Sliney J Jr, Silverberg SJ, Bilezikian JP, Muller R. Three dimensional cancellous bone structure in hypoparathyroidism. Bone. 2010 Jan;46(1):190-5. doi: 10.1016/j.bone.2009.09.020. Epub 2009 Sep 25.
Reference Type
BACKGROUND
Fong J, Khan A. Hypocalcemia: updates in diagnosis and management for primary care. Can Fam Physician. 2012 Feb;58(2):158-62.
Reference Type
BACKGROUND
Cusano NE, Rubin MR, Sliney J Jr, Bilezikian JP. Mini-review: new therapeutic options in hypoparathyroidism. Endocrine. 2012 Jun;41(3):410-4. doi: 10.1007/s12020-012-9618-y. Epub 2012 Feb 7.
Reference Type
BACKGROUND
Straub DA. Calcium supplementation in clinical practice: a review of forms, doses, and indications. Nutr Clin Pract. 2007 Jun;22(3):286-96. doi: 10.1177/0115426507022003286.
Reference Type
BACKGROUND
Bilezikian JP, Cusano NE, Khan AA, Liu JM, Marcocci C, Bandeira F. Primary hyperparathyroidism. Nat Rev Dis Primers. 2016 May 19;2:16033. doi: 10.1038/nrdp.2016.33.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AMCS-009
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Phase 3 Study of KHK7580 for the Treatment of Hypercalcemia in Patients With Parathyroid Carcinoma or Primary Hyperparathyroidism
NCT03280264
COMPLETED
PHASE3
Evaluate Safety and Efficacy of Paricalcitol in Reducing Serum Intact Parathyroid Hormone in Chronic Kidney Disease
NCT01071070
COMPLETED
PHASE3
A Study to Assess the Efficacy and Safety of Paricalcitol in the Treatment of Chronic Kidney Disease With Secondary Hyperparathyroidism
NCT04994080
UNKNOWN
PHASE3
A Pilot Clinical Study Evaluating the Effect of Parathyroid Hormone (PTH) Lowering On Erythropoietin Consumption in Calcitriol-Resistant Patients
NCT01506947
COMPLETED
PHASE4
Management of Mineral and Bone Disease in Hemodialysis-Calcitriol vs. Paricalcitol
NCT01725113
TERMINATED
PHASE4
A Study of an Investigational Medication for the Treatment of Secondary Hyperparathyroidism in Patients on Dialysis
NCT00042653
COMPLETED
PHASE3
Study of the PTH-independent Effects of Encaleret on Mineral Homeostasis in Subjects With Postsurgical Hypoparathyroidism (PSH)
NCT05735015
COMPLETED
PHASE2
Paricalcitol Injection Phase II Trial
NCT00646932
COMPLETED
PHASE2
Paricalcitol Compared to Maxacalcitol in Chronic Kidney Disease Patients With Secondary Hyperparathyroidism
NCT00990704
COMPLETED
PHASE2
Safety and Efficacy of CTAP101 to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D Insufficiency
NCT01704079
COMPLETED
PHASE3
Study of the Influence of Dosages of 1-84 and 7-84 Fragments of Parathyroid Hormone Compared to Conventional Dosage on the Balance of Calcium and Phosphate in Hemodialysis (PTH)
NCT02859220
COMPLETED
NA
A Study of an Investigational Medication for the Treatment of Secondary Hyperparathyroidism in Dialysis Patients
NCT00037635
COMPLETED
PHASE3
Intravenous Paricalcitol in Chronic Hemodialysis Patients
NCT03023748
UNKNOWN
PHASE4
Dose-response Study of Paricalcitol Injection in Chronic Kidney Disease Patients Receiving Hemodialysis
NCT00667576
COMPLETED
PHASE2
Study of MT1013 for the Treatment of Patients With Secondary Hyperparathyroidism
NCT07122401
RECRUITING
PHASE3
Cinacalcet for Secondary Hyperparathyroidism in Patients Receiving Hemodialysis
NCT00446329
TERMINATED
PHASE4
ACHIEVE: Optimizing the Treatment of Secondary Hyperparathyroidism
NCT00135304
COMPLETED
PHASE4
Cinacalcet HCl in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism Not Receiving Dialysis
NCT00094484
COMPLETED
PHASE3
Initial Dosing of Paricalcitol in Secondary Hyperparathyroidism
NCT00307840
COMPLETED
PHASE4
Evaluation of the Effectiveness of Paricalcitol Versus Cinacalcet With Low-Dose Vitamin D
NCT00977080
COMPLETED
PHASE4
Efficacy of Calcium Citrate Versus Calcium Carbonate for the Management of Chronic Hypoparathyroidism
NCT03425747
COMPLETED
PHASE4
Pyrophosphate Homeostasis and Hepatic Expression of ABCC6.Pyro-TH
NCT03576859
COMPLETED
NA
Comparison of Efficacy and Safety of Paricalcitol Injection With Maxacalcitol Injection in Adult Japanese Chronic Kidney Disease Subjects Receiving Hemodialysis With Secondary Hyperparathyroidism
NCT01341782
COMPLETED
PHASE3